Gain Therapeutics (GANX) Stock Price, News & Analysis

Company Overview

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Key Stats

• Today's Range: $1.61 to $1.75
• 50-Day Range: $1.43 to $2.92
• 52-Week Range: $0.89 to $5.33
• Volume: 141,791 shs
• Average Volume: 289,301 shs
• Market Capitalization: $44.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Buy

Gain Therapeutics Stock Analysis - MarketRank™

Gain Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 614th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Gain Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.05) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gain Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gain Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Gain Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.72% of the float of Gain Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gain Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gain Therapeutics has recently increased by 15.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gain Therapeutics does not currently pay a dividend.

Dividend Growth

Gain Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.72% of the float of Gain Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gain Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gain Therapeutics has recently increased by 15.09%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.44

News Sentiment

Gain Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Gain Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.70% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.97% of the stock of Gain Therapeutics is held by institutions.

GANX Stock Analysis - Frequently Asked Questions

How have GANX shares performed this year?

Gain Therapeutics' stock was trading at $3.27 at the beginning of 2024. Since then, GANX shares have decreased by 49.2% and is now trading at $1.66.
View the best growth stocks for 2024 here.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) announced its earnings results on Thursday, August, 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.11.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an initial public offering on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Who are Gain Therapeutics' major shareholders?

Top institutional shareholders of Gain Therapeutics include Geode Capital Management LLC (1.07%). Insiders that own company stock include Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder.
View institutional ownership trends.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Gain Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GANX
• CUSIP: N/A
• CIK: 1819411
• Web: www.gaintherapeutics.com
• Phone: 301-500-1556
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.33
• High Stock Price Target: $8.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +341.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -203.91%
• Return on Assets: -128.05%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 2.99
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $50,000.00
• Price / Sales: 880.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.97 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 26,525,000
• Free Float: 23,422,000
• Market Cap: $44.03 million
• Optionable: Optionable
• Beta: 0.33